294 related articles for article (PubMed ID: 36645666)
1. Circulating miRNAs associated with nonalcoholic fatty liver disease.
Atic AI; Thiele M; Munk A; Dalgaard LT
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
4. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
Liu XL; Pan Q; Zhang RN; Shen F; Yan SY; Sun C; Xu ZJ; Chen YW; Fan JG
World J Gastroenterol; 2016 Nov; 22(44):9844-9852. PubMed ID: 27956809
[TBL] [Abstract][Full Text] [Related]
5. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.
Kim TH; Lee Y; Lee YS; Gim JA; Ko E; Yim SY; Jung YK; Kang S; Kim MY; Kim H; Kim BH; Kim JH; Seo YS; Yim HJ; Yeon JE; Um SH; Byun KS
Sci Rep; 2021 Jul; 11(1):14639. PubMed ID: 34282172
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
[TBL] [Abstract][Full Text] [Related]
7. A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis.
Liu J; Xiao Y; Wu X; Jiang L; Yang S; Ding Z; Fang Z; Hua H; Kirby MS; Shou J
BMC Genomics; 2018 Mar; 19(1):188. PubMed ID: 29523084
[TBL] [Abstract][Full Text] [Related]
8. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Liu CH; Ampuero J; Gil-Gómez A; Montero-Vallejo R; Rojas Á; Muñoz-Hernández R; Gallego-Durán R; Romero-Gómez M
J Hepatol; 2018 Dec; 69(6):1335-1348. PubMed ID: 30142428
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers.
López-Riera M; Conde I; Quintas G; Pedrola L; Zaragoza Á; Perez-Rojas J; Salcedo M; Benlloch S; Castell JV; Jover R
Sci Rep; 2018 Jul; 8(1):10606. PubMed ID: 30006517
[TBL] [Abstract][Full Text] [Related]
10. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
11. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis.
Zhu Y; Tan JK; Wong SK; Goon JA
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298120
[TBL] [Abstract][Full Text] [Related]
13. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
[TBL] [Abstract][Full Text] [Related]
14. Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review.
Kan Changez MI; Mubeen M; Zehra M; Samnani I; Abdul Rasool A; Mohan A; Wara UU; Tejwaney U; Kumar V
J Int Med Res; 2023 Sep; 51(9):3000605231197058. PubMed ID: 37676968
[TBL] [Abstract][Full Text] [Related]
15. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway.
Samy AM; Kandeil MA; Sabry D; Abdel-Ghany AA; Mahmoud MO
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300631. PubMed ID: 38574101
[TBL] [Abstract][Full Text] [Related]
16. Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
Kennedy L; Meadows V; Sybenga A; Demieville J; Chen L; Hargrove L; Ekser B; Dar W; Ceci L; Kundu D; Kyritsi K; Pham L; Zhou T; Glaser S; Meng F; Alpini G; Francis H
Hepatology; 2021 Jul; 74(1):164-182. PubMed ID: 33434322
[TBL] [Abstract][Full Text] [Related]
17. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
Salvoza NC; Klinzing DC; Gopez-Cervantes J; Baclig MO
PLoS One; 2016; 11(4):e0153497. PubMed ID: 27077736
[TBL] [Abstract][Full Text] [Related]
18. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.
Estep M; Armistead D; Hossain N; Elarainy H; Goodman Z; Baranova A; Chandhoke V; Younossi ZM
Aliment Pharmacol Ther; 2010 Aug; 32(3):487-97. PubMed ID: 20497147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
